Indo-U.S. Vaccine Action Program

The Indo-U.S. Vaccine Action Program (VAP) is a bilateral program, which supports a broad spectrum of activities relating to immunization and vaccine related research. The program was designed to encompass laboratory-based research, epidemiological studies, field trials, vaccine quality control, and delivery of vaccines.

Main Areas of Focus

  • Priorities under VAP currently include: dengue, enteric diseases, influenza (including avian influenza), malaria, and tuberculosis (TB)
  • The program has been further expanded to include initiatives focused on TB clinical research and human immunology
  • Additional areas of interest include research on antimicrobial resistance, chikungunya vaccines, infant immunology and respiratory syncytial virus (RSV)


All work is carried out within areas designated as priorities by the VAP Joint Working Group (JWG), which is comprised of scientists and officials from both countries. The JWG establishes the policies and scientific directions for the program, makes decisions on major activities, and provides scientific oversight and evaluation.


Collaboration in science and technology has been an enduring feature of the U.S.-India relationship for over three decades. Cooperation in the health sciences has been particularly prominent. Special initiatives have been undertaken over the years in an effort to advance cooperation more rapidly and effectively in some areas. One of the most important and successful of these has been the Indo-U.S. Vaccine Action Program (VAP).

Program background


Research awards to promote specific U.S-India collaborations in the context of the VAP are made to U.S. institutions through the NIAID Division of Microbiology and Infectious Diseases (DMID) and other NIAID divisions.

Read more about program funding
Content last reviewed on